行情

NBY

NBY

NOVABAY PHARMA
AMEX

实时行情|Nasdaq Last Sale

0.5800
-0.0294
-4.82%
已收盘, 16:00 11/12 EST
开盘
0.5800
昨收
0.6094
最高
0.6177
最低
0.5600
成交量
32.14万
成交额
--
52周最高
4.040
52周最低
0.2290
市值
1,618.31万
市盈率(TTM)
-1.0670
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

NBY 新闻

  • NovaBay Pharmaceuticals, Inc. (NBY) CEO Justin Hall on Q3 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.2天前
  • The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut
  • Benzinga.4天前
  • NovaBay EPS beats by $0.06, misses on revenue
  • seekingalpha.5天前
  • NovaBay Pharmaceuticals Q3 EPS $(0.02) Beats $(0.08) Estimate, Sales $1.615M Miss $2.05M Estimate
  • Benzinga.5天前

更多

所属板块

生物技术和医学研究
+0.45%
制药与医学研究
+0.31%

热门股票

名称
价格
涨跌幅

NBY 简况

NovaBay Pharmaceuticals, Inc., formerly NovaCal Pharmaceuticals, Inc., is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox. Its Avenova with Neutrox removes debris from the skin on the eyelids and lashes without burning or stinging. It develops additional products containing Neutrox, including its NeutroPhase Skin and Wound Cleanser for wound care and CelleRx for the dermatology market. Its Aganocide compounds, led by auriclosene (NVC-422), are synthetic molecules with activity against bacteria, viruses and fungi. The Company's dermatology product includes CelleRx, a cleansing solution for post laser resurfacing, chemical peels and other cosmetic surgery procedures. Its wound care business includes the business of NeutroPhase product.
展开

Webull提供NovaBay Pharmaceuticals, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。